# US 2006/0233717 A1 · Delivery of compounds for the treatment of headache through an inhalation route

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0233717 A1
- Document ID: US20060233717A1
- Status: Published application
- Kind: A1
- Application number: 11/385,992
- Filed: 2006-03-21
- Published: 2006-10-19
- Earliest claimed: 2001-05-24
- Assignees: Alexza Pharmaceuticals, Inc.
- Inventors: Ron Hale; Joshua Rabinowitz; Dennis Solas; Alejandro Zaffaroni
- Web page: https://patentgrep.com/patent/US20060233717A1

## CPC

- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to the delivery of migraine headache drugs through an inhalation route. Specifically, it relates to aerosols containing migraine headache drugs that are used in inhalation therapy.

## Claims

### Claim 1

A dose form of sumatriptan comprising a condensation aerosol formed by heating a thin layer containing sumatriptan, on a solid support, to produce a vapor of sumatriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% sumatriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 20 mg of sumatriptan.

### Claim 2

A dose form of frovatriptan comprising a condensation aerosol formed by heating a thin layer containing frovatriptan, on a solid support, to produce a vapor of frovatriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% frovatriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 2 mg of frovatriptan.

### Claim 3

A dose form of naratriptan comprising a condensation aerosol formed by heating a thin layer containing naratriptan, on a solid support, to produce a vapor of naratriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% naratriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 0.8 mg of naratriptan.

### Claim at position 4

4-6. (canceled)
